文献速递艾滋病与性传播感染

塞克硝唑单剂口服治疗女性滴虫病的疗效与安全性:3期随机双盲安慰剂对照延迟治疗研究

Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项3期随机双盲安慰剂对照延迟治疗研究在美国10个中心纳入147名经培养确诊的滴虫病女性,比较单剂口服塞克硝唑2g与安慰剂的微生物学治愈率。改良意向治疗人群中,塞克硝唑组治愈率92.2%,安慰剂组1.5%,差异显著;塞克硝唑耐受性良好,最常见不良事件为外阴阴道念珠菌病和恶心(各2.7%)。

要点

  • 单剂口服塞克硝唑2g治疗女性滴虫病微生物学治愈率显著高于安慰剂。
  • 合并HIV或细菌性阴道病的女性中塞克硝唑治愈率分别为100%和95.2%。
  • 塞克硝唑总体耐受性良好,未观察到严重治疗中出现的不良事件。

核心结论

  • 单剂口服塞克硝唑2g与安慰剂相比显著提高女性滴虫病的微生物学治愈率。
  • 塞克硝唑可用于治疗女性滴虫病,包括合并HIV和/或细菌性阴道病的患者。

研究设计与样本

  • 3期随机双盲安慰剂对照延迟治疗研究,在美国10个中心开展。
  • 2019年4月至2020年3月共入组147名经阴道毛滴虫培养确诊的滴虫病女性。
  • 改良意向治疗人群包括131名随机化患者(塞克硝唑组n=64,安慰剂组n=67)。
  • 主要终点为给药后6-12天培养法微生物学治愈(TOC),TOC访视时给予相反治疗。

主要发现

  • 合并HIV女性治愈率为100%(4/4),合并细菌性阴道病女性治愈率为95.2%(20/21)。
  • 最常见治疗中出现的不良事件为外阴阴道念珠菌病和恶心(各2.7%),未观察到严重不良事件。

临床怎么用

  • 对于培养确诊的女性滴虫病患者,可考虑单剂口服塞克硝唑2g作为治疗选择。
  • 合并HIV或细菌性阴道病的滴虫病女性也可使用塞克硝唑治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection. We evaluated the efficacy and safety of secnidazole vs placebo in women with trichomoniasis. METHODS: Women with trichomoniasis, confirmed by a positive T. vaginalis culture, were randomized to single-dose oral secnidazole 2 g or placebo. The primary endpoint was microbiological test of cure (TOC) by culture 6-12 days after dosing. At the TOC visit, participants were given the opposite treatment. They were followed for resolution of infection afterward and offered treatment at subsequent visits, if needed. Fifty patients per group (N = 100) provided approximately 95% power to detect a statistically significant difference between treatment groups. RESULTS: Between April 2019 and March 2020, 147 women enrolled at 10 sites in the United States. The modified intention-to-treat (mITT) population included 131 randomized patients (secnidazole, n = 64; placebo, n = 67). Cure rates were significantly higher in the secnidazole vs placebo group for the mITT population (92.2% [95% confidence interval {CI}: 82.7%-97.4%] vs 1.5% [95% CI: .0%-8.0%]) and for the per-protocol population (94.9% [95% CI: 85.9%-98.9%] vs 1.7% [95% CI: .0%-8.9%]). Cure rates were 100% (4/4) in women with human immunodeficiency virus (HIV) and 95.2% (20/21) in women with bacterial vaginosis (BV). Secnidazole was generally well tolerated. The most frequently reported treatment-emergent adverse events (TEAEs) were vulvovaginal candidiasis and nausea (each 2.7%). No serious TEAEs were observed. CONCLUSIONS: A single oral 2 g dose of secnidazole was associated with significantly higher microbiological cure rates vs placebo, supporting a role for secnidazole in treating women with trichomoniasis, including those with HIV and/or BV. CLINICAL TRIALS REGISTRATION: NCT03935217.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Muzny CA, Schwebke JR, Nyirjesy P, et al. Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. Clin Infect Dis. 2021. PMID: 33768237. doi:10.1093/cid/ciab242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。